1. Cynthia Cynthia United States says:

    An FDA advisory panel just recommended  that the warning for Covidien’s Optimark and GE’s Omnisca—drugs in the family of medications known as gadolinium-based contrast agents (DBCAs) be updated to restrict their use in patients with severe kidney disease because of the potential for an increased risk of nephrogenic systemic fibrosis (NSF). NSF causes thickening of the skin and organs. GBCAs carry a strong “black box” warning.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.